1. Ziektemodulerende Behande-ling van multiple sclerose bij volwassenen: addendum bij de richtlijn multiple sclerose 2012. Nederlandse Vereniging voor Neurologie. Disease modifying treatments for multiple sclerosis in adults: addendum to the multiple sclerosis guideline 2021. Dutch association for neurology. https://www.msnetwerk.nl/wp-content/uploads/2020/03/Bijlage-2-clean-Richtlijn-Ziektemodulerende-Behandeling-van-Multiple-Sclerose-bij-volwassenen-%E2%80%93-28-2-2020-1.pdf. Accessed October 28, 2021.
2. Ziektemodulerende behandeling van mutiple sclerose bij volwassenen: addendum bij de richtlijn multiple sclerose [Disease modifying treatment for multiple sclerosis in adults: addendum to the multiple sclerosis guideline.];Smolders;Tijdschr Neurol Neurochir,2021
3. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States;Kern;BMC Neurol,2020
4. Monitor MS-Geneesmiddelen 2019. Zorginstituut Nederland. Monitor MS-drugs. https://www.zorginstituutnederland.nl/publicaties/rapport/2019/06/13/monitor-ms-geneesmiddelen-2019. Accessed October 28, 2021.
5. Modeling the cost-utility of treatment sequences for multiple sclerosis;Huygens;Value Health,2021